Pyxis Oncology is trading 5.6% lower at $3.04 amid a broader biotech sell-off.
- Biotech ETF XBI is down 2.04% during regular trading as higher Treasury yields, elevated oil prices and inflation concerns pressure growth-oriented healthcare stocks.
- No new company-specific announcement dated September 24, 2026 was identified; the latest notable update was positive MICVO Phase 1 data released September 9.